Approvals

The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes.
 
People with Type 2 diabetes do not produce or respond normally to insulin, a hormone that regulates the amount of glucose in the blood. Over time, high blood glucose levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage.
 

European Commission Approves Orencia in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis

European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis

•Data show ORENCIA offers durable and sustained long-term efficacy

PR Newswire US - Jul. 02, 2010

WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication.

PR Newswire Europe & UK Disclose - Jul. 06, 2010